Article

Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology

2025-12-15

Abstract excerpt

The landscape of first-line treatment for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations is rapidly evolving, currently dominated by pembrolizumab-based regimens. This review discusses the unique molecular characteristics of cemiplimab, a newer anti-PD-1 antibody, and defines its optimal positioning against established standards. Cemiplimab is a fully human IgG4 monoclonal antibo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 92db57ce-f2fc-556a-9a77-66811f21acb0
DOI: 10.20944/preprints202512.1249.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous HistologyDOI 10.20944/preprints202512.1249.v1Read

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapySemantic proximity Read

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1.Semantic proximity Read

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.Semantic proximity Read

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read

From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration.Semantic proximity Read

Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials.Semantic proximity Read

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read

Non–Small Cell Lung Cancer Metastatic Without Oncogenic AlterationsSemantic proximity Read

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).Semantic proximity Read

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?Semantic proximity Read

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity Read